Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Collegium Pharmaceutical Inc
COLL | US
33.27
USD-0.11
-0.33%
COLL | US
Loading StockChartView...
About Collegium Pharmaceutical Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
08/06/2026
Close
33.27
Open
33.46
High
33.68
Low
33.11
Collegium Pharmaceutical Inc. a specialty pharmaceutical company develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily around-the-clock long-term opioid treatment; Nucynta ER and Nucynta IR which are extended-release and immediate-release formulations of tapentadol; Belbuca a buccal film that contains buprenorphine; and Symproic an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals Inc. and changed its name to Collegium Pharmaceutical Inc. in October 2003. Collegium Pharmaceutical Inc. was incorporated in 2002 and is headquartered in Stoughton Massachusetts.
View LessCOLL | US
Risk
40.5
Sharpe
0.20
Luna's Score
36/100
Recommendation
Sell
Luna says (COLL | US)
What's Working
Strong Operating Margin (> 25%)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
48.5%1 month
40.5%3 months
42.2%6 months
39.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
14.45
Fwd. PE
5.81
Price to book
5.79
Debt to equity
2.58
Debt to assets
0.53
Ent. to EBITDA
4.31
Ent. to rev.
2.67
PEG
-
Other Fundamentals
EBITDA
347.36M
MarketCap
1.07B
MarketCap(USD)
1.07B
Div. yield
-
Op. margin
32.68
Erngs. growth
52.30
Rev. growth
7.20
Ret. on equity
47.87
Short ratio
16.06
Short perc.
22.85
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
5.00
Range1M
7.70
Range3M
10.37
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.07
Price X volume
14.05M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 4.31 | 24.85 | Cheaper |
| Ent. to Revenue | 2.67 | 361.91 | Cheaper |
| PE Ratio | 14.45 | 30.05 | Cheaper |
| Price to Book | 5.79 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 42.20 | 65.24 | Lower Risk |
| Debt to Equity | 2.58 | -1.88 | Expensive |
| Debt to Assets | 0.53 | 0.48 | Par |
| Market Cap | 1.07B | 3.71B | Emerging |
